mupirocin and Herpes-Zoster

mupirocin has been researched along with Herpes-Zoster* in 1 studies

Other Studies

1 other study(ies) available for mupirocin and Herpes-Zoster

ArticleYear
[Topical ozone therapy: An innovative solution to patients with herpes zoster].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2018, Feb-28, Volume: 43, Issue:2

    To observe the clinical efficacy and safety of topical ozone therapy for patients with herpes zoster by reflectance confocal microscopy (RCM).
 Methods: A total of 60 patients with herpes zoster were divided into a control group and an ozone treatment group (n=30). In the control group, patients took oral valacyclovir tablets or granules (0.3 g per day, three times a day) and they were subjected to local weak laser irradiation treatment plus topical 2% mupirocin ointment twice a day. In the ozone group, the treatment is same as the control group except mupirocin ointment was replaced with topical ozone treatment (hydrotherapy every day plus ozonated oil twice a day). The clinical symptoms, discoid cell and adverse reactions were observed and taken records at day 0, 3, 7 and 14. Statistical analysis was performed to compare the clinical efficacy between the 2 groups. 
 Results: On the seventh day of treatment, the discoid cells of the ozone group disappeared, and the difference between the control group and the ozone group was statistically significant (P<0.05). The difference of decreased percentage of pain scores at each time point between the 2 groups was statistically significant (P<0.05). The clinical efficacy was 100% in the ozone group and 86.7% in the control group, with significant difference between the 2 groups (P<0.05).
 Conclusion: Topical ozone therapy in patients with herpes zoster is helpful in relieving pain, shortening the course as well as improving the clinical efficacy without obvious adverse reactions. It is worth to be popularized.. 目的:应用反射式共聚焦显微镜(reflectance confocal microscope,RCM)观察臭氧外用治疗带状疱疹的临床疗效及安全性。方法:将60例带状疱疹患者分为对照组和臭氧组(n=30)。对照组口服伐昔洛韦片剂或颗粒剂(每日300 mg,每日3次),同时采用局部弱激光照射治疗,外用2%莫匹罗星软膏(每日2次);臭氧组将莫匹罗星改为臭氧水湿敷(每日1次)和臭氧油外用(每日2次),分别在治疗前和治疗的第3,7,14天观察临床症状和体征的变化,并用RCM检测靶部位水疱内圆盘状细胞的变化,比较两组的临床疗效并记录不良反应。结果:治疗第7天,臭氧组包涵体消失,与对照组比较,差异有统计学意义(P<0.05);各时间点臭氧组疼痛评分下降百分比明显高于对照组(P<0.05);臭氧组患者总有效率为100%,对照组为86.7%,两组比较差异有统计学意义(P<0.05);两组患者均未见明显不良反应和并发症发生。结论:臭氧外用治疗带状疱疹有助于缓解患者疼痛、缩短病程、提高临床疗效,无明显不良反应,值得临床推广应用。.

    Topics: Acyclovir; Administration, Oral; Administration, Topical; Antiviral Agents; Case-Control Studies; Combined Modality Therapy; Drug Administration Schedule; Herpes Zoster; Humans; Hydrotherapy; Low-Level Light Therapy; Microscopy, Confocal; Mupirocin; Oils; Ozone; Pain Management; Pain Measurement; Treatment Outcome; Valacyclovir; Valine

2018